ArticleCancer immunology, immunotherapy : CII2026
Real-world outcomes of ipilimumab plus nivolumab in esophageal squamous cell carcinoma: a multi-institutional large cohort study.
Shuichiro Hara et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.